B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12
B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.
Stocks · News reference
Candel Therapeutics Starts Pivotal Phase 3 AURORA Study Of Aglatimagene Besadenovec Plus Valacyclovir In Combination With Continued Pembrolizumab In Participants With Metastatic Non-Squamous Non-Small Cell Lung Cancer
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.
Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.23) by 126.09 percent. This is a 477.78 percent decrease over losses of $(0.09) per
8-K filing — Candel Therapeutics, Inc. (CADL)
Filed: 2026-08-13 AccNo: 0001193125-26-347957 Size: 371 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits